N/A N=22 Combined Brain and Peripheral Nerve Stimulation for Stroke
Stroke
Primary: Active Range of Motion of Wrist Extension in the Paretic Side — 37.8; 38; 37.2; 38 degrees
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=15 Cancer Anorexia and the Central Nervous System
Cancer Cachexia
Primary: ACTIVATION/NON ACTIVATION OF SPECIFIC BRAIN AREAS, EVALUATED BY FUNCTIONAL MAGNETIC RESONANCE — 585.57; 667.92; 511.22 BOLD
N/A N=36 Brain Function and Decision-Making
Behavior, Social · Psychology, Social · Social Interaction
Primary: Change in Prefrontal Cortex Brain Activity Assessed by fMRI — -0.002; 0.015 Percent BOLD Signal Change
N/A N=76 Neural Basis of Sensory and Motor Learning: Functional Connections
Basic Science
Primary: Resting-state PMv-M1 Functional Connectivity (Fisher Z-transformed Correlation) — 0.64 unitless (Fisher z-score)
N/A N=22 Hypoglycemia and Autonomic Nervous System Function
Hypoglycemia
Primary: Change in Baroreflex Sensitivity — 2.3; -1.6 ms/mmHg
Phase 2 N=30 The Efficient Brain Study
Metabolism - Cerebral Energy
Primary: Magnetic Resonance Spectroscopy (MRS) Will Measure a Change in Cerebral Energy Function in Brain Tissue — .011; .007; .009; .006 Difference in metabolite amplitude
Phase 2 N=27 Bevonescein to Highlight Nerves in Patients Undergoing Head & Neck Surgery
Parotid Neoplasm · Thyroid Neoplasms · Head and Neck Neoplasms
Primary: Safety - The Number of Patients With ALM-488 Related Adverse Events — 0; 0; 0; 0 Participants
Phase 4 N=10 Effect of Antibiotics on Enteric Neurons and Glia
Antibiotic Enterocolitis
Primary: Change in Mean Number of Colonic Submucosal Neurons/mm^2 in the Colon After Antibiotic Treatment — 0 neuronal cells/mm^2
N/A N=92 Neuroproprioceptive "Facilitation, Inhibition" and Brain Plasticity
Multiple Sclerosis
Primary: White Matter Integrity — 0.5023; 0.5168; 0.4747 score on a scale
N/A N=1 Providing Brain Control of Extracorporeal Devices to Patients With Quadriplegia
Tetraplegia
Primary: Number of Participants With Patient Control Over the End Effector (Virtual or Physical) — 1 Participants
N/A N=112 Nitric Oxide and the Autonomic Nervous System
Hypertension · Pure Autonomic Failure
Primary: Change in Systolic Blood Pressure — 43; 21 mm Hg
N/A N=35 Neural Bases of Cognitive Rehabilitation for Brain Injury
Brain Injury
Primary: Change From Baseline on a Composite Measure (Z-score) of Attention, Working Memory, and Executive Functions — 0.26; .01 Change to Z (composite) score
Phase 4 N=10 Functional Effects of Botox on the Brain Using MRS and fMRI
Healthy
Primary: Glutamate + Glutamine (Glx)/Creatine Ratio as Measured by MRS in the Brainstem Pre and Post-Botox — .12 Brainstem GLX/Cr
N/A N=24 Noninvasive Vagus Nerve Stimulation (VNS) for Neuromotor Adaptations
Healthy Young Adults
Primary: Visuomotor Skill — 1; 1; 0.870; 0.969 Ratio of the baseline value — p=0.0096
Phase 1 N=13 The Maraviroc Central Nervous System (CNS) Study
HIV Infections
Primary: CSF (Cerebrospinal Fluid) : Plasma Ratio of Maraviroc 1H Magnetic Resonance Spectroscopy (1H-MRS) — 1.01 ratio
Phase 4 N=31 The Relationship Among Changes in Brain Network Activation in Adult Outpatients With Major Depressive Disorder
Major Depressive Disorder
Primary: Change in Montgomery and Asberg Depression Rating Scale (MADRS) — 33.28; 16.23 score on a scale — p=<0.001
N/A N=18 Brain Markers of Improvements in Cognitive Functioning
TBI (Traumatic Brain Injury) · Brain Injuries · Stress
Primary: Composite Score of Attention and Executive Functioning From a Neurocognitive Test Battery — 0.18; -0.06 units on a scale
N/A N=26 Brain Stimulation and Enhancing Cognition in Older Adults
Cognitive Impairment, Mild · Depressive Symptoms · Anxiety
Primary: Cognitive and Memory Function — 56.5; 49.8 score on a scale
Phase 4 N=21 Network-Level Effects of Nitrous Oxide in the Human Brain
Healthy
Primary: Functional Connectivity During Nitrous Oxide — 0.1123; 0.0358; 0.1492; 0.0394 Fisher's r transformed z score — p=0.001
N/A N=40 Brain and Coordination Changes Induced By Robotics and FES Treatment Following Stroke
Cerebral Stroke · Cerebrovascular Accident · Stroke
Primary: AMAT — 1693; 1693; 1556; 1386 seconds
N/A N=20 Electrophysiologic Studies of Cognition in Epilepsy Patients
Drug-resistant Epilepsy
Primary: Heartbeat Evoked Potential (HEP) for Attention — -1.5 µV
N/A N=16 Neural Underpinnings of Turning
Aging
Primary: Duration of Cortical Silent Period (CSP) (ms) — 104.34; 99.71 milliseconds (ms)
Phase 2 N=10 Intranasal Administration of Neuropeptide Y in Healthy Male Volunteers
Mood Disorder · Anxiety Disorders
Primary: Levels of NPY in CSF — 329.4; 351.0 pg/mL
N/A N=56 The Autonomic Nervous System and the Metabolic Syndrome
Obesity
Primary: Insulin Resistance — 3.8; 3.1 mg/kg/min
N/A N=12 Central Sodium Sensing: Implications for Blood Pressure Regulation
Salt Sensitivity of Blood Pressure
Primary: Functional Connectivity Between the Subfornical Organ and Organum Vasculosum of the Lamina Terminalis (Z-score) — 0.258490; 0.359145; 0.207372; 0.169055 z-score
N/A N=15 Brain Stimulation and Cognitive Training - Efficacy
Schizophrenia · Schizo Affective Disorder · Bipolar Disorder
Primary: Change in Working Memory Performance - Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB)…
N/A N=45 The BRAIN App: Building Relationships Using Artificial Intelligence and Nostalgia
Dementia · Dementia, Vascular · Alzheimer Disease
Primary: Change From Baseline to Treatment for Constructive Engagement on the Menorah Park Engagement Scale — .72 score on scale — p=<0.01
N/A N=12 Brain Stimulation and Cognitive Training
Bipolar Disorder · Schizo Affective Disorder · Schizophrenia
Primary: Participant Retention in Combination Treatment — 4; 5 Participants
Phase 2 N=40 Neuronal Correlates of Neurexan® Action in Mildly to Moderately Stressed Probands
Acute Stress Reaction
Primary: Functional Magnetic Resonance Imaging (fMRI) Task Data: BOLD Activation Changes Within Amygdala During Negative Faces in the Hariri Face Matching Task Between Placebo…
Phase 2 N=30 Intranasal Inhalations of Bioactive Factors Produced by M2 Macrophages in Patients With Organic Brain Syndrome
Organic Brain Syndrome, Nonpsychotic · Neurocognitive Disorders · Mental Disorder, Organic
Primary: The Number of Patients With Severe Adverse Events and Adverse Reactions — 0 Participants